title: Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction.
abstract: OBJECTIVE
  To investigate the effect of the phosphodiesterase 5 (PDE5) inhibitor Tadalafil on bladder blood flow and bladder function in a rat model of partial bladder outlet obstruction (BOO).
  
  
  METHODS
  Female 14-15-week-old Sprague-Dawley rats were divided into three groups. BOO was surgically induced in rats by placing a rubber ring around the urethra. BOO rats were administered daily oral Tadalafil (BOO-Tadalafil) or vehicle (BOO-Vehicle), while sham-operated animals were treated with vehicle (Sham). On the 14th day after surgery, micturition behavior was recorded for 24 hr by using a metabolic cage. On the 15th day after surgery, bladder blood flow and bladder weight were measured. The expression of PDE5 mRNA in the vesical and iliac arteries of intact rats was measured by reverse transcriptase-polymerase chain reaction.
  
  
  RESULTS
  BOO led to a significant decrease in bladder blood flow and a significant increase in bladder weight. These changes were partially suppressed by Tadalafil treatment. The number of micturitions in the BOO group was significantly increased and the average micturition volume was significantly decreased, without affecting the total micturition volume. Repeated Tadalafil treatment markedly inhibited the increase in micturition frequency and the decrease in average micturition volume. PDE5 mRNA was expressed in the vesical and iliac arteries.
  
  
  CONCLUSIONS
  Tadalafil suppressed the reduction in bladder blood flow caused by BOO in rats and improved urinary function. This action of Tadalafil may contribute to its amelioration of bladder function. Neurourol. Urodynam. 35:444-449, 2016. © 2015 Wiley Periodicals, Inc.
authors.affiliation: Discovery Research Laboratories, Nippon Shinyaku Co., Ltd, Kyoto, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kawai
authors.affiliation: Discovery Research Laboratories, Nippon Shinyaku Co., Ltd, Kyoto, Japan.
authors.forename: Michiko
authors.initials: M
authors.lastname: Oka
authors.affiliation: Discovery Research Laboratories, Nippon Shinyaku Co., Ltd, Kyoto, Japan.
authors.forename: Ryohei
authors.initials: R
authors.lastname: Yoshinaga
authors.affiliation: Discovery Research Laboratories, Nippon Shinyaku Co., Ltd, Kyoto, Japan.
authors.forename: Chiaki
authors.initials: C
authors.lastname: Fuchikami
authors.affiliation: Discovery Research Laboratories, Nippon Shinyaku Co., Ltd, Kyoto, Japan.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Oyama
mesh_terms: D000818:Animals; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D009119:Muscle Contraction / Q000187:drug effects; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D000068581:Tadalafil / Q000494:pharmacology* / Q000627:therapeutic use; D001743:Urinary Bladder / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D014554:Urination / Q000187:drug effects
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D000068581:Tadalafil; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5
keywords: Tadalafil; benign prostatic hyperplasia; bladder blood flow; bladder outlet obstruction